Maryanne Maunsell Farris's most recent trade in Haemonetics Corp. was a trade of 2,662 Common Stock done . Disclosure was reported to the exchange on June 5, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Haemonetics Corp | Maryanne Maunsell Farris | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2025 | 2,662 | 4,478 (0%) | 0% | - | Common Stock | |
| Haemonetics Corp | Maryanne Maunsell Farris | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2025 | 1,732 | 1,732 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Haemonetics Corp | Maryanne Maunsell Farris | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2025 | 800 | 1,816 (0%) | 0% | - | Common Stock | |
| Haemonetics Corp | Maryanne Maunsell Farris | VP, Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 70.31 per share. | 15 May 2025 | 68 | 1,016 (0%) | 0% | 70.3 | 4,781 | Common Stock |
| Haemonetics Corp | Maryanne Maunsell Farris | VP, Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 69.38 per share. | 15 May 2025 | 60 | 1,084 (0%) | 0% | 69.4 | 4,163 | Common Stock |
| Haemonetics Corp | Maryanne Maunsell Farris | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2024 | 1,291 | 1,291 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Haemonetics Corp | Maryanne Maunsell Farris | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2024 | 587 | 1,144 (0%) | 0% | - | Common Stock | |
| Haemonetics Corp | Maryanne Maunsell Farris | VP, Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 96.49 per share. | 15 May 2024 | 73 | 557 (0%) | 0% | 96.5 | 7,044 | Common Stock |
| Haemonetics Corp | Maryanne Maunsell Farris | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2023 | 1,425 | 1,425 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Haemonetics Corp | Maryanne Maunsell Farris | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2023 | 630 | 630 (0%) | 0% | - | Common Stock |